For the 95% of rare disease patients still without an approved treatment, FDA is working for you.
Acting Commissioner Kyle Diamantas shares how FDA is transforming rare disease drug development through the new Rare Disease Framework Initiative. Because every family deserves answers, action, and hope. fda.gov/news-events/fda-voic…
Washington, D.C., may be buzzing today about the latest political fight and the withdrawal of Dr. Overton’s nomination.
But 2,000 miles away, life in our home goes on. And so does Duchenne.
The disease doesn't pause for political drama. It doesn't wait for a new @FDA commissioner. Every day, it keeps attacking my son's muscles. And every day, we have to keep fighting to preserve them.
Save the date and register for the Updates in Amyloidosis CME Conference, Jan. 29–30, 2027, at The Camby Hotel in Phoenix, AZ.
Patients, care partners, healthcare professionals, and researchers are welcome.
swamyloidconference.org/regi…#Amyloidosis#AmyloidosisEducation
Brilliant, informed, insightful.
Every person with a #RareDisease should read this baseline qualification list by @houmanhemmati then contact your Senators, Senate HELP Committee members and Senate Rare Disease Caucus members to ensure that the next FDA Commissioner meets these minimum qualifications and that the next confirmation hearings focus on rare diseases.
30M Americans have a rare disease and most have no disease-modifying treatments. We need the next #FDA Commissioner to prioritize & expedite drug approvals. The risk of delay, denial -- "doing nothing" -- can have lethal consequences.
2026 HELP Committee Senators
DEMS:
🔹Bernie Sanders (VT) 202-224-5141 -- Chair
🔹Patty Murray (WA) 202-224-2621
🔹Tammy Baldwin (WI) 202-224-5653
🔹Chris Murphy (CT) 202-224-4041
🔹Tim Kaine (VA) 202-224-4024
🔹Maggie Wood-Hassan (NH) 202-224-3324
🔹John Hickenlooper (CO) 202-224-5941
🔹Ed Markey (MA) 202-224-2742
🔹Andy Kim (NJ) 202-224-4744
🔹Lisa Blunt Rochester (DE) 202-224-2441
🔹Angela Alsobrooks (MD) 202-224-4524
GOP:
🔹Rand Paul (KY) 202-224-4343 -- Ranking Member
🔹Lisa Murkowski (AK) 202-224-6665
🔹Tim Scott (SC) 202-224-6121
🔹Josh Hawley (MO) 202-224-6154
🔹Jim Banks (IN) 202-224-4814
🔹Mike Crapo (ID) 202-224-6142
🔹Julia Letlow (LA) 202-224-5824
The new HELP Committee members for the 120th Congress won't be named until Dec/Jan. But you can contact these existing members now as many will continue to be on the committee next session.
SENATE RARE DISEASE CAUCUS MEMBERS:
Roger Wicker (MS) 202-224-6253 -- CoChair
John Boozman AR 202-224-4843
Tom Cotton (AR) 202-224-2353
Ruben Gallego (AZ) 202-224-4521
Alex Padilla (CA) 202-224-3553
Richard Blumenthal (CT) 202-224-2823
Chris Coons (DE) 202-224-5042
Lisa Blunt Rochester (DE) 202-224-2441
Raphael Warnock (GA) 202-224-3643
Chuck Grassley (IA) 202-224-3744
Jim Risch (ID) 202-224-2752
Jerry Moran (KS) 202-224-6521
John Kennedy (LA) 202-224-4623
Ed Markey (MA) 202-224-2742
Chris Van Hollen (MD) 202-224-4654
Angus King (ME) 202-224-5344
Elissa Slotkin (MI) 202-224-4822
Roger Wicker (MS) 202-224-6253
John Hoeven (ND) 202-224-2551
Andy Kim (NJ) 202-224-4744
James Lankford (OK) 202-224-5754
Jeff Merkley (OR) 202-224-3753
Jack Reed (RI) 202-224-4642
Maria Cantwell (WA) 202-224-3441
Shelley Moore-Capito (WV) 202-224-6472
John Barrasso (WY) 202-224-6441
@HELPCmteDems@GOPHELP@SenMarkKelly@SenRubenGallego@AbdulElSayed@AbdulElSayedHQ@AnnieAndrewsMD@SenGillibrand#ALS#Huntingtons#Duchenne#ataxia#EndALS#EndHD
The FDA Commissioner role is open again. Dr. Heidi Overton’s nomination was pulled the night before her Senate committee vote. Whatever the internal reasons, this creates a rare opening to get the leadership right for American patients and for the innovation that actually reaches them.
Here’s what the next Commissioner needs to be. Not a wish list. A baseline:
You cannot regulate what you have never lived. The person in this seat should have spent real time on the other side of the table—building a product in biotech, pharma, or devices—and felt the weight of regulatory decisions as the recipient (sometimes the victim). That experience is not optional. Career government officials and pure academics can be talented, but they have never had a program delayed, a trial redesigned, or a company nearly killed by a decision whose full consequences they never had to carry. The ethics rules make it extremely difficult for anyone with industry experience to take this job because of the divestiture requirements. The result is that the role often defaults to people who have never created anything. That may be administratively easier. There is a price.
This person must be a licensed physician—ideally a physician-scientist—who has done both basic and clinical research and who has actually taken care of patients. An active license is ideal. They need to understand, firsthand, what patients face, including patients with rare diseases. For many of those conditions it is mathematically nearly impossible to hit a p-value of 0.05, the arbitrary threshold we treat as the definition of statistical significance. That reality has to be lived, not just read about.
The role is sacred. It involves life-and-death decisions for millions of people. It is therefore not a platform for partisan ideology. Americans are sick of extreme partisanship. The next Commissioner should be objective, serve all Americans, and recognize that this job is not subject to partisan manipulation. They should be blindly loyal to exactly one large and powerful special-interest group: THE AMERICAN PEOPLE. Full stop.
They should be well-spoken and confident in public settings, yet humble enough to welcome feedback and constructive criticism.
They should not arrive with their mind made up on specific drugs or classes of drugs before they have seen the data. The FDA’s job is not to decide whether a particular patient should receive a particular drug. That decision belongs to the physician and the patient once the science is sound and the information is clear. Every regulatory choice carries 2 risks: the risk of approving something that later proves harmful, and the risk of not approving something that could have helped. Both are real. For patients with serious or rare conditions and few options, the second risk is often larger.
This is also a national-security position. It requires a counterintelligence background check (don’t ask how I know 😉) for a reason: the wrong decision or the wrong public (or private) statement can do real harm. The person who holds it should treat that responsibility with the seriousness it deserves—focused on the work, not on being a constant public figure, & never hinting at confidential information.
They may hold strong personal, cultural, or religious beliefs. Those beliefs stay at the door. The job is to follow the law and to do what is medically, scientifically, and ethically right for American patients.
Bring back open, FAIR advisory committee meetings so the public can see how decisions are made. Keep asking not only “Is it safe enough to approve?” but “What happens if we do not?” Protect the public from products that offer real risk with no benefit, while trusting informed patients and physicians when credible evidence exists that a treatment can help
This is a moment to choose leadership that is responsive to the needs of all Americans—objective, compassionate, and thoughtful. American patients & American innovation are counting on it.
Good riddance! Heidi Overton's comments at her confirmation hearing were less than convincing in response to one single question by @SenatorCollins re rare diseases. And not one democrat asked a question about FDA policy affecting the 30M Americans battling rare diseases.
Overton's nomination raised alarms in the #RareDisease community because of her long professional relationship with former Commissoner Marty Makary, who was an obstacle to rare disease drug approvals.
Makary mentored Overton as a surgery resident at Johns Hopkins, advised her doctoral research, and collaborated with her on published works.
Like Overton, both Makary and Vinay Prasad publicly promoted President Trump's mandate to “deliver more cures and meaningful treatments.” But those words were empty promises. They overruled review teams on accelerated approval, moved the goal posts on agreed SAPs, and cancelled AdComms that give dying patients a voice. Ultimately, the FDA issued 23 CRLs for #RareDisease treatments.
Nothing in her confirmation hearing nor in her work on the DPC assuaged our communities that Overton would act differently.
People who have been #DyingWaiting cannot afford a Commissioner who will derail all the progress and commitments made by @FDA_KyleD.
The next nominee must be better.
The Senate must do better at the next HELP confirmation hearing.
@POTUS@GOPHELP@HELPCmteDems@BernieSanders@SenSanders@SenBillCassidy@lisamurkowski@PattyMurray@SenatorWicker@SenGillibrand@AbdulElSayed@AnnieAndrewsMD#healthcare#ClinicalTrials#FDA#Orphandisease#ALS#Huntingtons#Duchenne#Ataxia#EndHD#EndALS#EndDuchenne
BREAKING: Overton's window has slammed shut. The WH has dropped Heidi's nomination for FDA commissioner amid struggles to get several Republican senators to a yes vote on her. washingtonsun.com/administra…
Elijah Stacey echos how my 33 year old son with Duchenne feels. My son doesn't have time for the Democrats and The President to make a deal! Everyone diagnosed with Duchenne deserves options!
Check out my latest piece in @theblaze on the FDA’s upcoming November 22 decision on deramiocel. The FDA has a chance to show rare disease patients that its promises were more than just talk. theblaze.com/columns/opinion…
Check out my latest piece in @theblaze on the FDA’s upcoming November 22 decision on deramiocel. The FDA has a chance to show rare disease patients that its promises were more than just talk. theblaze.com/columns/opinion…
Call your Senators to vote NO.
The GAO is critical to provide unbiased oversight. We cant afford 15 yrs of agencies doing whatever they damn well please. GAO ensures agencies dont act with paternalism or corruption.
This should be a much bigger story.
Senate Republicans are rushing to install a Trump insider as the federal government's top watchdog for the next 15 years. The hearing is this Thursday, and hardly anyone is paying attention.
The Government Accountability Office is how Congress keeps any president honest about your money. It audits spending, uncovers waste and fraud, and calls out illegality.
Trump's pick to lead GAO is Eric Ueland, the No. 2 official in Russ Vought’s budget office. If Ueland is confirmed, you can kiss accountability goodbye.
Whoever gets this seat stays through several future presidencies.
The law asks a bipartisan commission of congressional leaders to recommend candidates. It never met. Republicans scheduled the hearing before a nominee was even named, racing to finish before they lose the Senate in January.
Call your senators and tell them to stop this nomination.
politico.com/news/2026/11/16…
For 27 years, the Pediatric Brain Tumor Consortium worked to save kids with brain cancer. But just before 5-year-old Ryleigh Schecter was diagnosed, the government shut it down.
A child with diagnosed D.I.P.G. will usually get six weeks of radiation five days a week. After that there is no proven treatment, no standard of care. The average time between diagnosis and death is nine to 12 months. Knowing this, parents will consent to anything. They will move. They will quit their jobs. They will sign forms acknowledging that under experimental treatment, their child may suffer painful or debilitating side effects. Yet even under the care of the most brilliant oncologists, the disease is likely to progress.
Diffuse intrinsic pontine glioma usually strikes between 4 and 10 years old, with about 300 children a year diagnosed in the United States. It grows in the brainstem, which controls the primary functions of human life: breathing, balance, the heartbeat. There, it meshes with the tissue, “like sand in grass,” clinicians say. For these reasons, it is inoperable.
No one wants their child to become “a human guinea pig,” as Amanda Schecter put it to me, but when the choice is between that and nothing, there is no choice. Of course, the Schecters want to help science. But first they want to save their child.
When the Schecter family went looking for clinical trials, one avenue of hope had recently been closed. In August 2025 the National Cancer Institute, part of the National Institutes of Health, terminated the Pediatric Brain Tumor Consortium, long a cornerstone of the government’s pediatric brain cancer effort. When the government did not renew the consortium’s $4 million annual grant, eight ongoing trials were closed or paused. Described publicly as a consolidation to improve efficiencies, the closure was part of the Trump administration’s sweeping moves to upend the government’s approach to federal research funding.
The Pediatric Brain Tumor Consortium — 16 elite pediatric hospitals in the country working together to test novel treatments for D.I.P.G. and other brain cancers — usually ran six to eight active clinical trials a year. Most were Phase 1 trials, a drug or therapy’s first step toward government approval. When the government defunded the consortium, researchers at its member hospitals were testing a promising immunotherapy and were about to test a laser therapy. For D.I.P.G., they were experimenting with a skull cap that sends electricity directly into the brains of patients; they were also testing a vaccine.
The D.I.P.G. trials were once available through the consortium at multiple sites within half a day’s drive of Ryleigh’s home, according to Kara Buente, who helps families like the Schecters find trials through her nonprofit, The Bella Project. Both were paused. Ryleigh does not have access to either of them.
nytimes.com/2026/11/15/well/…
30M Americans with #RareDiseases often have NO HEALTHCARE. As chair of @HELPCmteDems please pass new legislation related to @FDA:
1️⃣ Codify a new FDA Conditional Approval Pathway for terminal rare diseases that mirrors the urgency and post market confirmation of Emergency Use Authorization pathway.
2️⃣Ensure FDA acts consistently with 21st Century Cures Act passed in 2016. FDA has ignored real world evidence and patient experience for the past decade.
FDA CBER has repeatedly refused to advance cell therapies with little safety risk. That office is well-known to be the most conservative despite CURES' mandate to advance "regenerative medicines."
See @SenGillibrand's 2026 statements at @SenateAging hearing.
3️⃣Enact legislation to ensure FDA "shall" consider opinions of top rare disease experts who were PIs or treating specialists -- important as FDA posesses no equivalent rare disease expertise. The "substantial evidence" definition in FDCA specifically requires experts to "EVALUATE & CONCLUDE" whether a therapy works.
Yet past FDA frquently IGNORED opinions of expert PIs from Mayo, Stanford, Cleveland Clinic, MGH, Vanderbilt, Dana Farber, MSK, U Chicago, Northwestern and National Childrens Hospital etc
4️⃣ Codify standards for risk-benefit analyses that FDA shall consider: irreparable harm from Type II error of delay or denial; of patients' tolerance for risk; of benefit from P4 post-marketing study.
5️⃣Mandate FDA "shall" act consistently across divisions. It has violated due process & the Administrative Procedures Act requirement to "treat like things alike," applying different standards to terminal rare disease therapies than cancer therapies.
6️⃣ Codify regulatory flexibility and fit-for-purpose efficacy standards. FDA has ignored and inconsistently applied their own regulations to exercise the broadest of "regulatory flexibility" in terminal diseases despite this being a long-standing mandate (snce 1988) in Subpart E (312.80 & 314.05) and in its own guidance documents.
7️⃣Codify standards for AdComms in rare diseases.
#rarediseases#HealthCare#Medicare#MedicareForAll@SenSanders@BernieSanders@PattyMurray@SenatorBaldwin@ChrisMurphyCT@SenTimKaine@SenatorHassan@AndyKimNJ@SenLBR@AnnieAndrewsMD@AbdulElSayed@lisamurkowski@SenMarkey@RandPaul
Powerful story on how the Trump administration killed the Pediatric Brain Tumor Consortium nytimes.com/2026/11/15/well/… which was so crucial for children with DMG/DIPG (rapidly fatal brain tumors) & their families. My lab studies DMG & more efforts are needed on it, not less
New AL Lambda light chain #amyloidosis study being launched by sponsor who developed tafamadis for people with #ATTR amyloidosis.
Lambda is a subtype of AL amyloidosis. It is ~3x more common than kappa subtype and has slightly worse survival. It has more frequent kidney and neurological involvement. But at diagnosis, patients have lower creatinine and lower baseline dFLC and Free Light Chain ratio.
Amyloidosis is a hetereogeneous rare disease affecting ~80k Americans. AL amyloidosis is only 1 of 42 types of amyloidosis. Appx 18k people are living with AL amyloidosis. Of the 4k new AL diagnoses in the US each yr, appx 75% are lambda AL and 25% are kappa AL subtype.
Thx to Protege Bio for investing in our community.
Mom had amyloidosis for nearly a decade before being diagnosed then died 7 months later because there were no disease modifying treatments.
#hematology#clinicaltrials#rarediseases
Potential game-changing oral stabilizing treatment for lambda light chain amyloidosis coming to clinical trial early 2027 by ProtegoBio nder Shield-AL. These are the folks who developed the ATTR stabilizer tafamidis.
Russ Hudson, the man who appeared in Scott Colom’s “pick another protein ad,” was once a homeless veteran who struggled with substance abuse.
He appeared in this news segment from 2019
A Texas veteran who is wheelchair-bound just had her VA-funded home care cut from 58 hours a week to 14 — her caretaker helps her shower, use a lift to get in bed, and change her. Her home health company says it's the same story for all 30 veterans they serve.
Read this compelling 11-pg letter to @FDA CBER from #deramiocel's trial investigators, who are renowned #Duchenne experts.
The legal standard for approval of an investigational therapy is "substantial evidence” of effectiveness, which is defined as evidence from adequate and well-controlled clinical investigations….
"(b) conducted by “experts qualified by scientific training and experience to EVALUATE the effectiveness of the drug involved, on the basis of which it could fairly and responsibly be CONCLUDED by such experts that the drug will have the effect it purports to have.”
21 U.S.C. § 355(d) (emphasis added).
Not only does the statute require the FDA consider expert opinions but in all diseases but especially in #RareDiseases where the FDA possesses no equivalent expertise, it is critical to heed the opinions of the expert neurologists and cardiologists who know #Duchenne the best.
@FDA_KyleD@FDAdrugs and Karim Mikhail
Please apply the principles of the new proposed Rare Disease Framework and urgently grant accelerated approval of @Capricor's cell therapy before these boys and young men suffer more irreparable harm.
Thank you to Craig M. McDonald, MD and the other PIs for fighting so vociferously for your patients' lives.
#EndDMD#Neurology#neurologist#pediatrician#MuscularDystrophy#orphandisease
👇🏽Link to letter in comments
$CAPR
I cannot think of any other clinical trial in which EVERY clinical trial investigator, world experts in the field who dedicate their lives to treating the disease in question, sign a letter to the @FDA urging approval.
Today, that happened as it relates to the pending FDA decision on deramiocel for Duchenne Muscular Dystrophy (DMD) from @Capricor$CAPR, a product I worked on in its very early days.
I urge everyone to take the time to read this letter in its entirety. It's clear that there's a clear and compelling case why these boys & young men, their parents and their physicians should not be denied the opportunity to make an informed choice for themselves, based on the available data and their individual circumstances. There's so much more to any clinical trial than numbers on a chart can depict, and this is one case where that couldn't be more true.
I pray that DMD patients be given the chance to decide for themselves, to try the drug should they and their physician make that decision, and to have some hope for preserving upper limb function when that is all they have left.
On November 11, the AP called Mississippi’s Senate race for Scott Colom. I’ve spent most of this year telling you how bad things are in this country, and I wasn’t wrong. But Mississippi is about to send a Black senator to Washington for the first time since 1881. Look at what that state was, and how recently.
1) Mississippi sent the first Black senator in American history. Hiram Revels was seated in 1870, in the seat Jefferson Davis had left to run the Confederacy. Blanche K. Bruce followed in 1875 and left in 1881. Mississippi didn’t send another Black senator for 145 years.
2) In 1890 the state rewrote its constitution to take the vote away from Black citizens. Six years later its own Supreme Court said so. The convention, the court wrote in Ratliff v. Beale, set out to “obstruct the exercise of the franchise by the negro race.”
3) Part of that constitution is still law. Section 241 bans people convicted of certain crimes from voting for life, and the framers picked the crimes they thought Black people were likelier to commit. A Fifth Circuit panel struck it down in August 2023. The full Fifth Circuit put it back in July 2024.
4) Statewide candidates also had to carry a majority of state House districts on top of the popular vote. That rule was written to stop Black-backed candidates. Mississippi voters got rid of it in November 2020.
5) Mississippi’s constitution banned interracial marriage until 1987, twenty years after Loving v. Virginia. The repeal got about 52% of the vote.
6) What about the 13th Amendment, the one that abolished slavery? Mississippi didn’t certify its ratification until February 2013.
7) In May 2016 a federal judge ordered Cleveland, Mississippi to desegregate its schools. That was 62 years after Brown v. Board of Education.
8) The Confederate battle emblem stayed on the state flag until 2020. Mississippi still marks Robert E. Lee’s birthday on the same day as Martin Luther King Jr. Day.
9) The last Democrat to win a Senate race in Mississippi was John Stennis, in 1982. Stennis signed the Southern Manifesto against integration in 1956. Stennis voted against the Civil Rights Act and the Voting Rights Act. Before any of that, as a prosecutor, he won death sentences for three Black men whose confessions came from whippings.
10) Colom beat Cindy Hyde-Smith. She went to a school founded to avoid integration. In 2018 she joked she’d be “on the front row” at a “public hanging,” in the state with the most recorded lynchings in America. In 2023 she blocked Colom from becoming a federal judge.
11) On November 3, Colom was at the Ice House in Jackson waiting on results. By November 11 he led by 4,669 votes on NBC’s count with 98.7% in, the race was called, and Hyde-Smith conceded.
I’m pessimistic about this country. I think I’ve earned it, and so have you. But organizers in Mississippi did this against every barrier the state could build, and I’m not going to pretend it didn’t happen. If we can’t let ourselves feel good about a win like this, we’ve already given up.